HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
View All | Scroll Down Scroll Up
Quote:
Login Free Membership
Search:

Analyst Blog  

AMO a Hold Post-Abbott Deal

Share
January 14, 2009 | Comment(s): 0
Recommended this article (6)
EYE | ABT

Advanced Medical Optics, Inc., or AMO (EYE) entered into a definitive agreement to be acquired by Abbott Laboratories (ABT - Analyst Report). Price appreciation on the stock is limited to the all cash transaction price of $22 per share or approximately $2.8 billion.

Our target price is equal to this cash transaction price and assumes the transaction will close. The company is a global leader in the development, manufacture, and marketing of medical devices for the eye and contact lens care products.

The stock is already trading near its cash transaction price. Thus, our target price is equal to this cash transaction price of $22 per share.

Read the full analyst report on EYE

Read the full analyst report on ABT


Read the full analyst report on EYE

Read the full analyst report on ABT

 

Please login to Zacks.com or register to post a comment.

Email
Print
Share
Rate Pos
Rate Neg
Attn. Zacks.com Visitors
7 Best Stocks for the Next 30 Days
Get your free Welcome Gifts today*:
 1.  Special Report with best short-term Zacks recommendations from the list that averages a gain of +26% per year
 2.  Our free e-newsletter with 4 "Strong Buy" stocks, Bull & Bear of the Day, and market commentary in every issue.
Get them free right now
  
No cost. Unsubscribe anytime. Privacy Policy
*Only for non-members. May end at any time.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

More Zacks Links

Market Summary May 25, 2012 08:26 am ET
DJIA 12529.75  0.00 0.00%
NASD 2839.38  0.00 0.00%
S&P 500 1320.68  0.00 0.00%
Partner Center

Top Zacks Features

Free Membership
Zacks Rank
Equity Research
Portfolio Tracker
Screening
Premium Screens
Mutual Funds
Options
Zacks Video
Education
RSS Feed
Profit from the Pros

Subscription Services

Product Guide
Method for Trading
Chart Patterns
FTM Trader
Home Run Investor
Income Plus
Insider Trader
Options Trader
Reitmeister Alert
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
People & Picks
Zacks Premium
Zacks Ultimate
Zacks.com: About Zacks | Education | Advertise | Affiliate | Media | Careers | Contact Us | Services | Help | Disclaimer | Privacy Policy | Sitemap

Copyright 2011 Zacks Investment Research

Zacks Investment Research is one of the most highly regarded firms in the investment industry. The guiding principle behind our work is that there must be a good reason for brokerage firms to spend billions of dollars a year on stock research. Obviously, these investment experts know something special that may be indicative of the future direction of stock prices. From day one, we were determined to unlock that secret knowledge and make it available to our clients to help them improve their investment results.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.